Hempsana

Overview

Despite unexpected challenges faced in 2020, the cannabis industry continues to grow, with the global cannabis edibles market alone expected to generate approximately USD $11,564 Million by 2025.

An integral component of the cannabis edibles market is cannabis extracts, which refer to a variety of cannabidiol (CBD) and tetrahydrocannabinol (THC) products processed from cannabis flowers into a concentrated form. These products allow consumers to ingest cannabis.

One company in the cannabis extracts industry is Hempsana (CSE:HMPS), which sets itself apart from other extraction companies as it focuses on providing well-engineered products and services that fuel its robust premier product development IP portfolio, as well as a focus on rare cannabinoids such as CBN, CBG and Delta-8 THC.

Hempsana operates with a goal to offer carefully crafted cannabinoid extracts for modern consumers looking for a safe and natural alternative, with products ranging from cannabinoid crude oil, distillate, to 99.9 percent pure cannabinoid isolates for Active Pharmaceutical Ingredient (API) use.

In under three years, Hempsana has received approval for CBD oil extraction in the European Union and an Industrial Hemp License from Health Canada, as well as a Standard Processing License from Health Canada.

Hempsana has established its reputation in the Canadian cannabinoid space by incorporating strict quality controls and extensive testing into its EU-GMP and GPP compliant facility. This allows access to wholesale and retail channels on a global scale and strategic partnerships in the EU, China, Asia, South America and Canada. Hempsana engages cannabinoid oil and isolate production and optimal cannabinoid formulation for cosmeceuticals, nutraceuticals and pharmaceutical use.

As a cannabis derivative company, Hempsana has tailored its extraction methodology and technologies to provide advanced cannabinoid solutions beyond CBD and THC into rare cannabinoids such as CBN, CBG, and Delta-8 THC.

Hempsana’s broad portfolio also includes “As-A-Service” offerings, wholesale distribution and white labeling. The company’s team of experts continuously explores and develops solutions and formulations for businesses to resell premium products that are customized and packaged for medical sales or for the recreational market.

Under this offering, a number of partnerships have been established for the development and manufacturing of CBD products for distribution to the medical-patient and the retail consumer channels.

“This partnership provides Hempsana a pathway into the medical consumer segment of the cannabis industry; more importantly, medical patients will gain access to high-quality cannabis products from Hempsana. By further diversifying our distribution channels we continue to execute on accelerating revenue growth by monetizing our expertise in the medical cannabis sector,” stated Hempsana CEO Randy Ko.

The next steps for the company include obtaining EU GMP certification for its facilities and developing exciting, rare and innovative cannabinoid products for retail markets in 2021.

Hempsana is headed by a world-class team of experts in the cannabis world. Randy Ko and his team have combined years of experience in capital markets, cannabis markets and regulatory affairs, which prime the company for economic success and growth as a leader in the Canadian cannabinoid space.

Hempsana’s Company Highlights

• Hempsana is a licensed cannabis extraction and purification company producing high-quality cannabinoid oils and cannabis-infused products.
• The company has diverse revenue streams consisting primarily of retail, wholesale and manufacturing channels.
• Hempsana offers high-quality cannabinoid products, including crude oil, distillates and isolates in increasingly high purities. Its services involve several avenues of revenue, including wholesale, Extraction-As-A-Service and white label service channels.
• The company leverages the limited rare cannabinoid space in Canada in hopes of carving a spot as a pioneer in high-quality extraction and processing of cannabinoids like CBN, CBG and Delta-8 THC.
• Hempsana looks forward to developing and delivering rare cannabinoid products to market, including innovative cannabinoid formulations for cosmeceuticals, nutraceuticals and pharmaceutical use.
• Hempsana holds a signed Letter of Intent with Canbud Distribution (CSE:CBDX, FSE:CD0) for the development and manufacturing of CBD products for distribution to Canbud’s medical-patient channel.